ADC Therapeutics Completes Enrollment for Promising Cancer Trial

ADC Therapeutics has wrapped up enrollment for their LOTIS-7 Phase 1b trial, which is testing the combo of ZYNLONTA and glofitamab in 100 patients with stubborn diffuse large B-cell lymphoma. They're super pumped about earlier results that showed high response rates and manageable safety. Full data is expected to drop at the end of 2026. What does it mean for you? If you're following cancer treatments or know someone who is, this trial could lead to new options for those with hard-to-treat lymphoma, potentially improving outcomes in the future.